Details for New Drug Application (NDA): 020613
✉ Email this page to a colleague
NDA 020613 describes ALPHAGAN, which is a drug marketed by Allergan and Abbvie and is included in four NDAs. Additional details are available on the ALPHAGAN profile page.
The generic ingredient in ALPHAGAN is brimonidine tartrate. There are eleven drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the brimonidine tartrate profile page.
The generic ingredient in ALPHAGAN is brimonidine tartrate. There are eleven drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the brimonidine tartrate profile page.
Summary for 020613
| Tradename: | ALPHAGAN |
| Applicant: | Allergan |
| Ingredient: | brimonidine tartrate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 020613
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION/DROPS;OPHTHALMIC | Strength | 0.2% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Sep 6, 1996 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
